Target intelligence / Profile preview

Cytochrome P450 3A1; Cytochrome P450 3A2 (CYP3A1; CYP3A2)

Target: CYP3A1; CYP3A2
Molecular classification: Enzyme, Monooxygenase, Cytochrome P450 superfamily

Overview

Cytochrome P4450 3A1/2 are rat-specific enzymes of the CYP3A subfamily localized mainly in the liver and intestine. They are homologous to human CYP3A enzymes—CYP3A4, CYP3A5, CYP3A7, and CYP3A43—and catalyze the metabolism of many endogenous substrates (steroid hormones, bile acids, lipids, vitamin D) and exogenous compounds (clinical drugs, toxins, carcinogens). CYP3A1/2 together account for a major portion of phase I drug metabolism in rats. They mediate oxidative reactions (hydroxylation, demethylation, and others) and are highly inducible or suppressible by various chemicals, determining metabolic fate and toxicity of substances. The combined designation "CYP3A1/2" is used mainly in preclinical pharmacokinetics or toxicology to refer to the main CYP3A enzymes in rats but is not a standard human target name.

Other names: CYP3A1 (rat)CYP3A2 (rat)Cytochrome P450 3A subfamily (rat)Cyp3a1/Cyp3a2

Mechanism of action

Oxidative metabolism (hydroxylation, N-/O-demethylation, S-oxidation, epoxidation), making lipophilic substances more hydrophilic for excretion Phase I metabolic transformation of drugs and endogenous molecules

Biological functions

Drug metabolismSteroid hormone catabolismLipid metabolismDetoxification of xenobioticsVitamin D metabolism

Disease associations

Cancer (role in carcinogen metabolism, toxicity)Other (altered drug metabolism affecting efficacy/toxicity, role in chemical toxicity)

Safety considerations

Drug-drug interactions arising from induction/inhibition of CYP3A enzymesAltered metabolism leading to therapy failure or toxicityAnimal models sometimes incompletely predict human CYP3A-mediated metabolism; species differences in expression and regulation

Interacting drugs

rifampin

9 more in the full profile.

Biomarkers

CYP3A1 or CYP3A2 expression/activity in rat liver/intestine are commonly used preclinical biomarkers for metabolic capacityProbe drugs (e.g., midazolam clearance rate) used to phenotype CYP3A activity

Beyond the preview

Go deeper on Cytochrome P450 3A1; Cytochrome P450 3A2 (CYP3A1; CYP3A2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome P450 3A1; Cytochrome P450 3A2 (CYP3A1; CYP3A2).

Explore the full profile